ClinicalTrials.gg
RecruitingNCT05907057Updated May 8, 2026

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

A Phase 3 interventional study of Ivosidenib 500mg Oral Tablet and Azacitidine in Acute Myeloid Leukemia (AML), sponsored by Servier Affaires Médicales. Recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Servier Affaires Médicales · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
245
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ivosidenib in Leukemia, Myeloid, Acute — 14 open to participants now, 19 under way, 4 of them phase 3. ivosidenib · Leukemia, Myeloid, Acute.

Planned enrollment
5th of 22
245 · median 72
Started
2023
with 1 other
Phase 3
3 of 22
1 open now
Primary completion
2027-10
later than 10 of 18 live
Registered
15th of 22
by date

Among the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute, this one is the 5th largest by planned enrollment, is one of 2 that started in 2023, is one of 3 in phase 3, reaches primary completion later than 10 of the 18 other live ones, and was the 15th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

14 of the 22 studies testing ivosidenib in Leukemia, Myeloid, Acute are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About ivosidenib

ivosidenib: first FDA approval 2018 (TIBSOVO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ivosidenib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about the safety and efficacy of ivosidenib taken with azacitidine to treat adult patients with acute myeloid leukemia (AML) who are presenting a gene mutation called IDH1 (isocitrate dehydrogenase1 mutation-positive [IDH1m]) and cannot receive treatment with intensive chemotherapy (IC).

Read the detailed description

Participants who are eligible and enroll in the study will attend a study visit on the first day of each 28-day cycle. Study visits will consist of a physical exam, blood work, electrocardiogram (ECG) and other assessments. After treatment discontinuation participants will be contacted every 12 weeks through the end of the study (currently planned for 2026) to assess survival. The study drug, Ivosidenib, will be taken once daily throughout the duration of participation in the study, and Azacitidine will only be administered for 7 days at the beginning of each 28 day cycle. If at any point ivosidenib is made available as a medical prescription at the patient's site, the patient will switch to commercial product and will continue to be followed according to the protocol.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • IDH1 Mutation AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has untreated Acute Myeloid Leukemia (AML)
  • Have a documented IDH1 R132 gene-mutated disease
  • Have at least one of the following making yourself ineligible for intensive chemotherapy (IC): 75 years or older, Performance Status (ECOG PS) of 2, or any comorbidity that the investigator judges to be incompatible with IC including but not limited to severe cardiac or pulmonary disorder, less than 45 mL/minute, or greater than 1.5 times the
  • Has adequate hepatic (liver) and renal (kidney) function
  • Female participants of must have a negative blood pregnancy test and must use effective during treatment and for at least 6 months following treatment
  • Fertile male participants with female partners of reproductive potential must use effective contraception during treatment and for at least 3 months following treatment

Exclusion criteria

Exclusion Criteria:

  • Has received any prior treatment for AML, with the exception of hydroxyurea or leukapheresis for white blood cell count control
  • Has received prior treatment with an IDH1 inhibitor
  • Is a woman who is pregnant or breastfeeding
  • Has an active, uncontrolled, systemic fungal, bacterial, or viral infection (including [HIV], active (HBV), or virus [HCV]) without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment
  • Has had significant active cardiac disease within 6 months prior to the start of study treatment, including Class III or IV congestive heart failure, myocardial infarction (heart attack), unstable angina (chest pain), and/or stroke
  • Has dysphagia (difficulty swallowing), short-gut syndrome, gastroparesis (stomach paralysis), or any other condition that limits the ingestion or gastrointestinal absorption of orally administered drugs
  • Has uncontrolled hypertension (high blood pressure)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
245 participants (estimated)

Study arms

  • Experimental
    Open-Label Ivosidenib in combination with Azacitidine

    All participants will receive both Ivosidenib and Azacitidine for a maximum of 28 cycles. Each cycle will be 4 weeks or 28 days long. Ivosidenib will be taken continuously throughout each cycle and Azacitidine will be taken only for 7 days at the beginning of each cycle.

    Drug: Ivosidenib 500mg Oral Tablet · Drug: Azacitidine

Interventions

  • Provided as tablets, taken orally as two 250mg tablets once daily.

  • Administered subcutaneously (SC) or intravenously (IV) at a dose of 75mg/m2/day for 7 days, either consecutively on Days 1-7 or discontinuously for Days 1-5 and 8-9 of each cycle. The 7 days of administration will occur at the beginning of every 4 week-long cycle.

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs)

    Adverse events (AEs) will be graded according to the CTCAE v5.0

    Time frame: up to week 116

  2. Number of Serious Adverse Events (SAEs)

    Adverse events (AEs) will be graded according to the CTCAE v5.0

    Time frame: up to week 116

  3. Differentiation Syndrome of Grade 2 or higher

    Time frame: up to week 116

  4. Number of Adverse Events (AEs) leading to ivosidenib + azacitidine discontinuation

    Time frame: up to week 112

  5. Number of Adverse Events (AEs) leading to ivosidenib + azacitidine interruption

    Time frame: up to week 112

  6. Number of Adverse Events (AEs) leading to ivosidenib + azacitidine dose reduction

    Time frame: up to week 112

  7. Number of Adverse Events (AEs) leading to death

    Time frame: up to week 116

  8. Number of clinical laboratory anomalies assessed as Adverse Events (AEs)

    Time frame: up to week 116

  9. Number of patients requiring transfusion (platelet and RBC) and the average number of units transfused

    Time frame: up to week 116

  10. Rate of infections

    Infection rates will be summarized by classification and will include a count and proportion.

    Time frame: up to week 116

  11. QT Prolongation event assessed as Grade 3 or higher

    Time frame: up to week 116

Secondary outcomes

  1. Event-free survival (EFS)

    Time frame: up to week 116

  2. Proportion of patients who achieve a complete remission (CR)

    Time frame: up to week 116

  3. Proportion of patients who achieve complete remission plus complete remission with partial hematologic recovery rate (CR + CRh)

    Time frame: up to week 116

  4. Proportion of patients who achieve complete remission plus complete remission with incomplete hematologic recovery rate (CR + CRi)

    Time frame: up to week 116

  5. Duration of response (DOR)

    Time frame: up to week 116

  6. Time to response (TTR)

    Time frame: up to week 116

  7. Overall survival (OS)

    Time frame: until study closure

  8. Quality of life (QoL), as measured by Hematologic Malignancy-Patient-Reported Outcome (HM-PRO)

    For patients with a baseline assessment and at least 1 post-baseline assessment that generates a score

    Time frame: up to week 116

  9. Quality of life (QoL), as measured by Family Reported Outcome Measure (FROM-16), for caregivers and/or family

    For patients with a baseline assessment and at least 1 post-baseline assessment that generates a score

    Time frame: up to week 116

  10. Health economic measures, as assessed by the 5-level EuroQol 5-Dimensions (EQ-5D-5L)

    For patients with a baseline assessment and at least 1 post-baseline assessment that generate a score

    Time frame: up to week 116

  11. Average proportion of days at home

    Defined by subtracting the number of care days (days hospitalized or seen in an ED / oncology clinic / infusion center) from the total days of follow-up, divided by total days of follow-up

    Time frame: up to week 116

07

Study locations

10 of 15 sites recruiting
08

References and documents

Publications

  • Vyas P, Salek S, Vives S, Recher C, Dohner H, Venditti A, Derrien H, Chatin S, De La Bigne AM, Pelouchova J, Hills R, Nier S. ALIDHE phase 3b study design: ivosidenib + azacitidine in adults with newly diagnosed IDH1 mutant acute myeloid leukemia. Future Oncol. 2025 Dec;21(29):3721-3729. doi: 10.1080/14796694.2025.2567838. Epub 2025 Nov 15. PubMed 41241779 ↗

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Data sharing details ↗ · clinicaltrials.servier.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Oct 2027, 52 months after the start.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's planned 52 months is above that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2023
First posted
Jun 18, 2023
StartActual
Jun 14, 2023
Primary completionEst.
Oct 15, 2027
CompletionEst.
Oct 15, 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05907057
Lead sponsor
Servier Affaires Médicales
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jun 14, 2023
Primary completion
Oct 15, 2027 (estimated)
Completion
Oct 15, 2027 (estimated)
Last update
May 8, 2026

Study contacts

Servier Affaires Médicales
Contact
scientificinformation@servier.com
+33 1 55 72 60 00

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ivosidenib · Azacitidine

Start the discussion